Content deleted Content added
Whispyhistory (talk | contribs) ce |
Whispyhistory (talk | contribs) ce |
||
Line 63: | Line 63: | ||
}} |
}} |
||
'''Olsalazine''' is an anti-inflammatory medication used in the treatment of |
'''Olsalazine''' is an anti-inflammatory medication used in the treatment of [[ulcerative colitis]]. It is sold under the brand name '''Dipentum'''.<ref name=Med1>{{cite web |title=Olsalazine Sodium 250 mg Capsules - Summary of Product Characteristics (SmPC) - (emc) |url=https://www.medicines.org.uk/emc/product/3708/smpc#gref |website=www.medicines.org.uk |access-date=9 January 2021}}</ref> |
||
Like [[balsalazide]], olsalazine is believed to deliver [[mesalazine]],<ref name=Med1/> or 5-aminosalicylic acid (5-ASA), past the small intestine, directly to the large intestine, which is the active site of disease in ulcerative colitis. |
Like [[balsalazide]], olsalazine is believed to deliver [[mesalazine]],<ref name=Med1/> or 5-aminosalicylic acid (5-ASA), past the small intestine, directly to the large intestine, which is the active site of disease in ulcerative colitis. |
Revision as of 20:05, 9 January 2021
![]() | |
Clinical data | |
---|---|
Trade names | Dipentum |
AHFS/Drugs.com | Monograph |
MedlinePlus | a601088 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | 99% |
Elimination half-life | 0.9 hours |
Identifiers | |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.116.494 |
Chemical and physical data | |
Formula | C14H10N2O6 |
Molar mass | 302.242 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Olsalazine is an anti-inflammatory medication used in the treatment of ulcerative colitis. It is sold under the brand name Dipentum.[2]
Like balsalazide, olsalazine is believed to deliver mesalazine,[2] or 5-aminosalicylic acid (5-ASA), past the small intestine, directly to the large intestine, which is the active site of disease in ulcerative colitis.
History
Olsalazine gained Food and Drug Administration (FDA) approval in 1990.
Supply
The drug is supplied by UCB Pharma.
Other indications
The Australian biotech company Giaconda has developed a combination therapy for treating constipation-predominant irritable bowel syndrome that uses olsalazine and the anti-gout drug colchicine.
References
- ^ a b "Olsalazine (Dipentum) Use During Pregnancy". Drugs.com. 6 September 2019. Retrieved 9 October 2020.
- ^ a b "Olsalazine Sodium 250 mg Capsules - Summary of Product Characteristics (SmPC) - (emc)". www.medicines.org.uk. Retrieved 9 January 2021.
External links
- "Olsalazine". Drug Information Portal. U.S. National Library of Medicine.